Actively Recruiting
Colchicine After Electrocardioversion for Atrial Fibrillation
Led by University Hospital, Basel, Switzerland · Updated on 2025-05-28
416
Participants Needed
8
Research Sites
150 weeks
Total Duration
On this page
Sponsors
U
University Hospital, Basel, Switzerland
Lead Sponsor
S
Swiss Heart Foundation
Collaborating Sponsor
AI-Summary
What this Trial Is About
The purpose of this study is to investigate whether a 3 month treatment course of low-dose Colchicine decreases the recurrence of Atrial fibrillation (AF) after electrocardioversion (ECV) in patients with AF.
CONDITIONS
Official Title
Colchicine After Electrocardioversion for Atrial Fibrillation
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Age greater than 18 years
- ECG-documented atrial fibrillation prior to electrocardioversion
- Successful electrocardioversion with conversion to sinus rhythm maintained for at least 30 minutes after the procedure
- Ability to provide written informed consent
You will not qualify if you...
- Atrial fibrillation persisting after cardioversion or early recurrence within 30 minutes after electrocardioversion
- Any heart rhythm other than atrial fibrillation before cardioversion
- Pulmonary vein isolation within 3 months before or planned within 3 months after electrocardioversion
- Known intolerance or allergy to Colchicine
- Any absolute reason requiring Colchicine use
- Use of strong CYP3A4 or P-Glycoprotein inhibitors (e.g., clarithromycin, erythromycin, telithromycin, cyclosporine, ketoconazole, itraconazole)
- Serious gastrointestinal disease such as severe gastritis or diarrhea
- Clinically obvious liver disease
- Severe kidney disease (estimated glomerular filtration rate less than 30 ml/min/1.73m2)
- Significant blood disorders like myelodysplasia
- Significant immune system suppression due to conditions like transplantation or rheumatic disease
- Pregnant or breastfeeding women, or women of childbearing potential not using highly effective contraception
- Life expectancy less than one year
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 8 locations
1
Cantonal Hospital Baselland (KSBL)
Bruderholz, Basel-Landschaft, Switzerland, 4101
Actively Recruiting
2
University Hospital Basel
Basel, Switzerland, 4031
Actively Recruiting
3
University Hospital Bern
Bern, Switzerland, 3010
Actively Recruiting
4
Lausanne University Hospital
Lausanne, Switzerland, 1011
Actively Recruiting
5
Lucerne Cantonal Hospital
Lucerne, Switzerland, 6000
Actively Recruiting
6
Cantonal Hospital Olten
Olten, Switzerland, 4600
Actively Recruiting
7
Herzpraxis am Rhein
Rheinfelden, Switzerland, 4310
Actively Recruiting
8
Solothurner Spitäler AG
Solothurn, Switzerland, 4500
Actively Recruiting
Research Team
P
Philipp Krisai, PD Dr. med.
CONTACT
How is the study designed?
Study Type
INTERVENTIONAL
Masking
TRIPLE
Allocation
RANDOMIZED
Model
PARALLEL
Primary Purpose
TREATMENT
Number of Arms
2
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here